BNGOHealthcare · Medical Instruments & SuppliesThe 2 Wall Street analysts covering Bionano Genomics, Inc. hold a median 12-month price target of $5 — +309.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 72 of 100 as at 22 Aug 2026 — in the upper half. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Bionano Genomics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (91): Smaller than most of the companies we track.
Value (19): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on BNGO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +309.8% from it.
Of the 20 most recent actions, 0 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | $7.00 → $6.00 |
| 13 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 24 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 18 Aug 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 20 May 2025 | Maxim Group | Upgrade | Buy | — |
| 9 Apr 2025 | HC Wainwright & Co. | Initiates | Buy | — |
| 2 Apr 2025 | Scotiabank | Maintains | Sector Perform | — |
| 15 Nov 2024 | Ladenburg Thalmann | Downgrade | Neutral | — |
| 10 Sept 2024 | BTIG | Downgrade | Neutral | — |
| 28 Aug 2024 | Scotiabank | Downgrade | Sector Perform | $6.00 → $1.00 |
| 16 May 2024 | BTIG | Maintains | Buy | — |
| 7 Mar 2024 | Scotiabank | Maintains | Sector Outperform | — |
| 13 Nov 2023 | Maxim Group | Downgrade | Hold | — |
| 10 Aug 2023 | BTIG | Maintains | Buy | — |
| 9 June 2023 | BTIG | Maintains | Buy | — |
| 25 May 2023 | EF Hutton | Initiates | Buy | $1.75 |
| 18 May 2023 | BTIG | Maintains | Buy | $3.00 → $2.00 |
| 24 Apr 2023 | BTIG | Maintains | Buy | — |
| 10 Mar 2023 | BTIG | Maintains | Buy | — |
| 6 Feb 2023 | Oppenheimer | Maintains | Outperform | $12 → $9.00 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BNGO appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 24 Aug 2026, Bionano Genomics, Inc. returned −69.5% against +19.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 74% of US stocks
Cheaper than 84% of US stocks
Cheaper than 86% of US stocks
Cheaper than 64% of US stocks
Higher than 71% of US stocks
Higher than 40% of US stocks
Higher than 61% of US stocks
Higher than 14% of US stocks
Higher than 5% of US stocks
Higher than 15% of US stocks
Higher than 13% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Bionano Genomics, Inc. has a market value of $14.1M and an enterprise value of $10.9M.
Revenue in the twelve months to 31 Mar 2026: $28.7M. The latest quarter grew 21.4% year on year.
Net income over the same four quarters: −$31.6M, a −109.9% net margin.
Diluted earnings per share, trailing twelve months: $−4.36.
Free cash flow in the twelve months to 31 Mar 2026: −$19.3M.
Trailing P/E: 0.0×; forward P/E: −1.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Bionano Genomics, Inc. employs 344 people — $84K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Bionano Genomics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Bionano Genomics announced that management will present and host 1x1 meetings at the H.C. Wainwright 28th Annual Global Investment Conference on Monday, September 14, 2026.
Why it matters — BNGO watchers would care because the company's management will present and hold one-on-one meetings with investors at a major investment conference, providing visibility into the company.
Bionano Genomics held its Q2 2026 earnings call and the transcript was published by Seeking Alpha. The call covered the company's financial results and operational update for the quarter.
Why it matters — BNGO watchers would care because earnings calls provide direct insight into the company's performance, strategy, and management's outlook.
Bionano Genomics announced it will report financial results for the second quarter of 2026 and host a conference call and live webcast on Monday, August 10, 2026, at 4:30 p.m. Eastern Time.
Why it matters — Investors and analysts tracking BNGO will be able to hear the company's second-quarter performance and any updates on recent corporate progress during the scheduled call.
The 2 Wall Street analysts covering Bionano Genomics, Inc. have a median 12-month price target of $5, with estimates ranging from $4 to $6. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 2 analysts covering Bionano Genomics, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Bionano Genomics, Inc. 72 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Bionano Genomics, Inc. ranks 72 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (91 of 100).
No one can know that. What the data says: the median 12-month target from 2 analysts implies +309.8% from the last close, and Ticker Nerd's factor model ranks Bionano Genomics, Inc. 72 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Bionano Genomics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BNGO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $6 over the next 12 months.
Bionano Genomics, Inc. returned -69.5% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Bionano Genomics develops genome analysis software that enables genomics laboratories to analyze and interpret genomic data across multiple platforms, generating comprehensive insights for research and clinical applications. The company's solutions are designed to detect genomic variations and provide a unified view of genome data, addressing critical questions in cancer diagnosis, genetic disease detection, and treatment planning.
The most recent item we track (GlobeNewsWire, 24 Aug 2026): "Bionano to Participate in the H.C. Wainwright 28th Annual Global Investment Conference". Bionano Genomics announced that management will present and host 1x1 meetings at the H.C. Wainwright 28th Annual Global Investment Conference on Monday, September 14, 2026.
Bionano Genomics develops genome analysis software that enables genomics laboratories to analyze and interpret genomic data across multiple platforms, generating comprehensive insights for research and clinical applications. The company's solutions are designed to detect genomic variations and provide a unified view of genome data, addressing critical questions in cancer diagnosis, genetic disease detection, and treatment planning. Bionano Genomics serves the genomics and clinical laboratory markets, offering tools that integrate data from various sequencing and analysis technologies. The company operates in the life sciences and healthcare technology sector, where it plays a role in advancing precision medicine and improving diagnostic capabilities for healthcare providers and research institutions worldwide.
CEO Dr. Robert Erik Holmlin M.B.A., Ph.D. · 344 employees · United States · https://www.bionano.com
